Determining a subject’s probability to suffer from pancreatic cancer

We have developed a novel, ELISA-based, pancreatic cancer diagnostic serum test.  Results so far are most promising and may render a breakthrough in diagnosis and thereby outcome of PDAC.

Pancreatic ductal adenocarcinoma (PDAC) has been reported as the fourth cause of cancer-related death and is prognosticated to become the second cause of death in cancer by the year 2020 if no breakthroughs occur. There is a need for improvement in early diagnosis, as well as improved and tumor-directed therapy.

There are risk groups e.g. hereditary forms of pancreatic cancer and not at least the association with diabetes mellitus type 2. 80 % of patients with diagnosed pancreatic cancer have a new onset (within the last two years prior to cancer diagnosis) diabetes mellitus type 2, or are in a prediabetic state. At this timepoint, patients are usually asymptomatic and when it comes to PDAC in general, symptoms are vague.

The novel biomarkers for PDAC, combined with carbohydrate antigen 19-9 renders an AUC of 0.95. We have several sets of validation, first in Sweden/ Scandinavia (about 200 patients), internationally (European; at least 600 patients), and under discussion a Chinese validation. We will evaluate if the diagnostic panel is expressed in serum in asymptomatic patients later developing pancreatic cancer, but with new onset diabetes mellitus.

A novel, ELISA-based, pancreatic cancer diagnostic serum test

Results from this ELISA-based, pancreatic cancer diagnostic serum test are promising.


Project leader Roland Andersson,, Lund University

Funding from SWElife 1 500 000 SEK

Call for proposal SWElife 2015 open call for “Predictive or prognostic biomarkers in tumour diseases”

About the project at Vinnova (in Swedish)